Developer docs
API playgroundTry for free, no card

Search company profiles

ImmunoForge

Full company profile

uuid000bf1l

Namestring
ImmunoForge
Legal namestring
ImmunoForge Co. Ltd.
Websiteurl
immunoforge.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

ImmunoForge Co. Ltd. is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, founded in 2017 by Sung-Min Ahn (MD-PhD) and Kiho Chang (MBA). The company develops treatments for rare musculoskeletal and related diseases using two proprietary technology platforms: the ELP (Elastin-Like Polypeptide) platform, which extends the circulating half-life of proteins and peptides by up to 200 times through temperature-dependent reversible phase transition, enabling weekly to monthly dosing from single subcutaneous injections; and the LMT15 platform, a next-generation blood-brain barrier shuttle combining leptin receptor-mediated transcytosis with ELP technology for CNS drug delivery.

ImmunoForge's pipeline spans eight core programs: Froniglutide (GLP-1R agonist in Phase 2 for Dermatomyositis/Polymyositis, also targeting DMD and sarcopenia), Pemziviptadil (VPAC2-targeting for DMD cardiomyopathy with FDA Phase 2 IND approval), PF1805 (CNP-ELP for achondroplasia), PF1806 (GLP-2-ELP for short bowel syndrome), PF1807 (once-monthly GLP-1R for sarcopenia), PF1802 (bifunctional biologic for ALS and Parkinson's), PF1803 (OSCAR+ targeting for osteoarthritis), and KF1601 (BCR-ABL T315I inhibitor for drug-resistant CML). The company holds five FDA Orphan Drug Designations and one MFDS ODD. IP assets include 88 patents acquired from PhaseBio in February 2023, supplemented by in-licensed technology from Duke University, Gachon University, Korea University, and Ewha Woman's University.

The business model is licensing-and-partnership-driven rather than commercial sales. ImmunoForge pursues out-licensing of Phase 2 assets and platform technologies to global pharmaceutical companies, co-development partnerships where partners provide development funding, and emerging NewCo investment structures for specific programs. The company has secured licensing deals with Boryung Corporation (KF1601), PharmGen Science (obesity formulation), and co-development agreements with Dong-A ST/NeuroBo (DA-1726 obesity) and Hamlet BioPharma (TB peptide slow-release). It maintains dual operations in Seoul and a US branch in King of Prussia, PA, targeting KOSDAQ listing in 2025-2026.

Short descriptiontext

ImmunoForge is a clinical-stage South Korean biopharmaceutical company developing long-acting protein/peptide therapeutics for rare neuromuscular diseases using its proprietary ELP half-life extension platform and LMT15 blood-brain barrier shuttle technology, monetizing via licensing and co-development deals with global pharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
half-life extension platform, long-acting biotherapeutics, rare disease therapeutics, polypeptide fusion drugs, clinical-stage biopharmaceutical
Industry4 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceutical — Rare Disease Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Technology Transfer
TypeLicensing Royalties
Description

The company generates revenue through global licensing agreements for its drug candidates and platform technologies, including out-licensing of Phase 2 assets PF1801 and PF1804, as well as ELP platform technology licensing to pharmaceutical partners.

prnewswire.com
2Co-development and Partnership Revenue
TypeProfessional Services
Description

Revenue from co-development partnerships where ImmunoForge contributes its platform technology while partners provide development funding and commercialization expertise. Examples include joint research with Dong-A ST/NeuroBo for obesity treatment.

morningstar.com
3NewCo Investment Structures
TypeLicensing Royalties
Description

The company is exploring NewCo (new corporation) models alongside traditional partnering arrangements to create standalone entities for specific therapeutic programs or platforms.

morningstar.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ImmunoForge is a clinical-stage biopharmaceutical company developing long-acting biologic drug candidates for rare neuromuscular, inflammatory, and metabolic diseases, using its proprietary ELP (Elastin-Like Polypeptide) half-life extension platform and LMT15 Blood-Brain Barrier shuttle platform. The company advances its own pipeline through Phase 2 clinical trials and generates revenue by out-licensing drug candidates and platform technologies to global pharmaceutical partners, while pursuing co-development agreements and NewCo structures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Half-life extension of drugs by up to 200 times compared to native formulations
+3 more records
Product overview1 text field

ImmunoForge is a clinical-stage biopharmaceutical company developing treatments for rare musculoskeletal diseases using its proprietary ELP (Elastin-Like Polypeptide) platform technology. The company's portfolio consists of two core technology platforms: the ELP Platform for half-life extension (up to 200x increase) enabling weekly/monthly dosing, and the LMT15 Platform for blood-brain barrier penetration using leptin receptor-mediated transcytosis. The product pipeline includes Froniglutide (GLP-1R agonist for DM/PM/DMD), Pemziviptadil (VPAC2 for DMD cardiomyopathy), PF1805 (CNP for achondroplasia), PF1806 (GLP-2 for short bowel syndrome), PF1807 (GLP-1R for sarcopenia), PF1802 (bifunctional for ALS/Parkinson's), PF1803 (OSCAR+ for osteoarthritis), and KF1601 (BCR-ABL for CML). Multiple assets have received FDA Orphan Drug Designation and are advancing through clinical trials.

Product and service3 records
1Froniglutide
CategoryLong-acting GLP-1 receptor agonist (rare disease biologic)
Description

A novel long-acting GLP-1 receptor agonist built on the ELP half-life extension platform, enabling once-weekly subcutaneous injection for the treatment of Dermatomyositis, Polymyositis, and Duchenne Muscular Dystrophy. Granted FDA Orphan Drug Designation for DMD (Dec 2020), FDA ODD for PM (Aug 2021), and MFDS ODD for DM/PM (Sep 2023). In Phase 2 for DM/PM with IND approval for Phase 2a in DMD.

2Pemziviptadil (PF1804)
CategoryVPAC2 receptor agonist biologic
Description

First-in-class ELP-engineered biologic targeting VPAC2 receptors, designed for once-weekly dosing to treat DMD cardiomyopathy, heart failure, and cystic fibrosis. FDA Orphan Drug Designation granted (May 2014); FDA Phase 2 IND approval for DMD cardiomyopathy (December 2024).

3PF1805
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Hamlet BioPharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Collaboration to develop novel slow-release administration technology for the peptide drug NZX, a drug candidate for pulmonary tuberculosis treatment. ImmunoForge will develop the slow-release technology to prolong the effect of each treatment, addressing antibiotic-resistant tuberculosis. Future research results and patent rights will be jointly owned by both companies.

news.cision.com
2Dong-A ST and NeuroBo Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-07
Description

Joint research agreement to develop a long-acting, once-monthly formulation of DA-1726 (a novel oxyntomodulin analog) for obesity treatment using ImmunoForge's ELP platform technology. Collaboration leverages ImmunoForge's half-life extension technology which can increase drug half-life by up to 200 times.

immunoforge.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-12
Description

Expanded research collaboration for ELP platform technology. Duke University holds rights for cancer applications while ImmunoForge holds development rights for other therapeutic areas. Both parties share profits from commercialization with global pharmaceutical companies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-08
Description

Joint research for antibody drug development combining ImmunoForge's fusion proteins with Korea University's long-acting Fc variant technology for rare disease treatments.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PTC Therapeutics is a US-based rare disease biotech with multiple DMD programs (e.g., Translarna, Emflaza) and a broader rare disease pipeline, making it a directly comparable commercial-stage peer to ImmunoForge's rare neuromuscular focus.

TypeDirect peer
Description

BridgeBio is a clinical-stage rare disease biotech pursuing multiple genetically targeted therapies, structurally similar to ImmunoForge in pursuing a broad pipeline of single-indication rare disease programs with multiple licensing/out-licensing opportunities.

TypeRegional player
Description

HanAll is a Korean clinical-stage biopharma with autoimmune and rare disease pipeline assets (e.g., batoclimab) and global out-licensing deals (with Immunovant, Roivant), making it the most directly comparable Korean regional peer to ImmunoForge in therapeutic focus and licensing-based GTM model.

TypeBroad incumbent
Description

Halozyme's ENHANZE platform is the leading commercial half-life extension technology (royalty-bearing deals with Roche, Pfizer, Janssen, etc.), making it the most directly comparable platform-licensing business model to ImmunoForge's ELP technology. Halozyme is more mature with a deep royalty stream from approved products.

TypeDirect peer
Description

Sarepta is the dominant commercial-stage biotech focused on Duchenne Muscular Dystrophy, directly overlapping with ImmunoForge's PF1801 (Froniglutide) and PF1804 (Pemziviptadil) DMD programs. Both companies target rare neuromuscular diseases with high unmet need and pursue FDA Orphan Drug Designations as a core regulatory strategy.

TypeDirect peer
Description

Amicus is a clinical-to-commercial rare disease biotech using protein engineering and biologics to address diseases of protein misfolding and deficiency, sharing with ImmunoForge a protein-engineering-driven therapeutic approach and a focus on rare diseases with no approved disease-modifying treatments.

TypeBroad incumbent
Description

BioMarin is an established rare disease biologics leader with a multi-product commercial portfolio and active late-stage pipeline, comparable in therapeutic focus (rare genetic disease) and biologic modality to ImmunoForge's pipeline, though much larger and commercially mature.

TypeDirect peer
Description

Ultragenyx is a clinical-to-commercial stage rare disease biotech developing biologics for genetic and metabolic diseases, with similar reliance on orphan drug exclusivity and a comparable pipeline-to-platform model. Their achondroplasia and short bowel programs directly overlap with ImmunoForge's PF1805 and PF1806.

TypeBroad incumbent
Description

Ionis is a clinical-to-commercial antisense/RNA therapeutics biotech with deep rare disease focus, sharing with ImmunoForge a half-life/extended dosing engineering emphasis, multiple partnered programs, and a reliance on FDA ODD pathways. Both also pursue novel enabling delivery technologies.

TypeRegional player
Description

GC Pharma (formerly Green Cross) is a major Korean biopharma with a biologics and rare disease focus, comparable to ImmunoForge as a Korean-listed biopharma pursuing therapeutic biologics, though much larger with commercial-stage products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImmunoForge

Clinical-stage Biopharmaceutical — Rare Disease Therapeuticsimmunoforge.com

ImmunoForge is a clinical-stage South Korean biopharmaceutical company developing long-acting protein/peptide therapeutics for rare neuromuscular diseases using its proprietary ELP half-life extension platform and LMT15 blood-brain barrier shuttle technology, monetizing via licensing and co-development deals with global pharma partners.

What ImmunoForge does

ImmunoForge Co. Ltd. is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, founded in 2017 by Sung-Min Ahn (MD-PhD) and Kiho Chang (MBA). The company develops treatments for rare musculoskeletal and related diseases using two proprietary technology platforms: the ELP (Elastin-Like Polypeptide) platform, which extends the circulating half-life of proteins and peptides by up to 200 times through temperature-dependent reversible phase transition, enabling weekly to monthly dosing from single subcutaneous injections; and the LMT15 platform, a next-generation blood-brain barrier shuttle combining leptin receptor-mediated transcytosis with ELP technology for CNS drug delivery.

ImmunoForge's pipeline spans eight core programs: Froniglutide (GLP-1R agonist in Phase 2 for Dermatomyositis/Polymyositis, also targeting DMD and sarcopenia), Pemziviptadil (VPAC2-targeting for DMD cardiomyopathy with FDA Phase 2 IND approval), PF1805 (CNP-ELP for achondroplasia), PF1806 (GLP-2-ELP for short bowel syndrome), PF1807 (once-monthly GLP-1R for sarcopenia), PF1802 (bifunctional biologic for ALS and Parkinson's), PF1803 (OSCAR+ targeting for osteoarthritis), and KF1601 (BCR-ABL T315I inhibitor for drug-resistant CML). The company holds five FDA Orphan Drug Designations and one MFDS ODD. IP assets include 88 patents acquired from PhaseBio in February 2023, supplemented by in-licensed technology from Duke University, Gachon University, Korea University, and Ewha Woman's University.

The business model is licensing-and-partnership-driven rather than commercial sales. ImmunoForge pursues out-licensing of Phase 2 assets and platform technologies to global pharmaceutical companies, co-development partnerships where partners provide development funding, and emerging NewCo investment structures for specific programs. The company has secured licensing deals with Boryung Corporation (KF1601), PharmGen Science (obesity formulation), and co-development agreements with Dong-A ST/NeuroBo (DA-1726 obesity) and Hamlet BioPharma (TB peptide slow-release). It maintains dual operations in Seoul and a US branch in King of Prussia, PA, targeting KOSDAQ listing in 2025-2026.

ImmunoForge firmographics

Firmographics
Name
ImmunoForge
Legal name
ImmunoForge Co. Ltd.
Website
https://immunoforge.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
ImmunoForge is a clinical-stage South Korean biopharmaceutical company developing long-acting protein/peptide therapeutics for rare neuromuscular diseases using its proprietary ELP half-life extension platform and LMT15 blood-brain barrier shuttle technology, monetizing via licensing and co-development deals with global pharma partners.
Ownership category
akta.pro rank

ImmunoForge industry classification

Industry
Product category
Clinical-stage Biopharmaceutical — Rare Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Half-life extension platform
  • Long-acting biotherapeutics
  • Rare disease therapeutics
  • Polypeptide fusion drugs
  • Clinical-stage biopharmaceutical

Where ImmunoForge is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

ImmunoForge business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Technology Transfer: The company generates revenue through global licensing agreements for its drug candidates and platform technologies, including out-licensing of Phase 2 assets PF1801 and PF1804, as well as ELP platform technology licensing to pharmaceutical partners.
  2. Co-development and Partnership Revenue: Revenue from co-development partnerships where ImmunoForge contributes its platform technology while partners provide development funding and commercialization expertise. Examples include joint research with Dong-A ST/NeuroBo for obesity treatment.
  3. NewCo Investment Structures: The company is exploring NewCo (new corporation) models alongside traditional partnering arrangements to create standalone entities for specific therapeutic programs or platforms.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

ImmunoForge product offering

Product offering

Core offering

ImmunoForge is a clinical-stage biopharmaceutical company developing long-acting biologic drug candidates for rare neuromuscular, inflammatory, and metabolic diseases, using its proprietary ELP (Elastin-Like Polypeptide) half-life extension platform and LMT15 Blood-Brain Barrier shuttle platform. The company advances its own pipeline through Phase 2 clinical trials and generates revenue by out-licensing drug candidates and platform technologies to global pharmaceutical partners, while pursuing co-development agreements and NewCo structures.

Product overview

ImmunoForge is a clinical-stage biopharmaceutical company developing treatments for rare musculoskeletal diseases using its proprietary ELP (Elastin-Like Polypeptide) platform technology. The company's portfolio consists of two core technology platforms: the ELP Platform for half-life extension (up to 200x increase) enabling weekly/monthly dosing, and the LMT15 Platform for blood-brain barrier penetration using leptin receptor-mediated transcytosis. The product pipeline includes Froniglutide (GLP-1R agonist for DM/PM/DMD), Pemziviptadil (VPAC2 for DMD cardiomyopathy), PF1805 (CNP for achondroplasia), PF1806 (GLP-2 for short bowel syndrome), PF1807 (GLP-1R for sarcopenia), PF1802 (bifunctional for ALS/Parkinson's), PF1803 (OSCAR+ for osteoarthritis), and KF1601 (BCR-ABL for CML). Multiple assets have received FDA Orphan Drug Designation and are advancing through clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Froniglutide A novel long-acting GLP-1 receptor agonist built on the ELP half-life extension platform, enabling once-weekly subcutaneous injection for the treatment of Dermatomyositis, Polymyositis, and Duchenne Muscular Dystrophy. Granted FDA Orphan Drug Designation for DMD (Dec 2020), FDA ODD for PM (Aug 2021), and MFDS ODD for DM/PM (Sep 2023). In Phase 2 for DM/PM with IND approval for Phase 2a in DMD.
  • Pemziviptadil (PF1804) First-in-class ELP-engineered biologic targeting VPAC2 receptors, designed for once-weekly dosing to treat DMD cardiomyopathy, heart failure, and cystic fibrosis. FDA Orphan Drug Designation granted (May 2014); FDA Phase 2 IND approval for DMD cardiomyopathy (December 2024).
  • PF1805

Quantifiable outcome

  • Half-life extension of drugs by up to 200 times compared to native formulations
  • +3 more outcomes

Companies that use ImmunoForge

Customer profile

Segments5 records

Ideal customer profiles2 records

ImmunoForge technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ImmunoForge partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Hamlet BioPharmacoreStrategic or Co-development Partner · 3 February 2026Collaboration to develop novel slow-release administration technology for the peptide drug NZX, a drug candidate for pulmonary tuberculosis treatment. ImmunoForge will develop the slow-release technology to prolong the effect of each treatment, addressing antibiotic-resistant tuberculosis. Future research results and patent rights will be jointly owned by both companies.
  • Dong-A ST and NeuroBo PharmaceuticalscoreStrategic or Co-development Partner · 7 August 2024Joint research agreement to develop a long-acting, once-monthly formulation of DA-1726 (a novel oxyntomodulin analog) for obesity treatment using ImmunoForge's ELP platform technology. Collaboration leverages ImmunoForge's half-life extension technology which can increase drug half-life by up to 200 times.
  • Duke UniversitycoreStrategic or Co-development Partner · 12 May 2023Expanded research collaboration for ELP platform technology. Duke University holds rights for cancer applications while ImmunoForge holds development rights for other therapeutic areas. Both parties share profits from commercialization with global pharmaceutical companies.
  • Korea University (Kang Taek-kyu Professor)minorStrategic or Co-development Partner · 8 December 2021Joint research for antibody drug development combining ImmunoForge's fusion proteins with Korea University's long-acting Fc variant technology for rare disease treatments.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

ImmunoForge competitors and assessment

Company assessment

Direct peers

  • PTC Therapeutics: PTC Therapeutics is a US-based rare disease biotech with multiple DMD programs (e.g., Translarna, Emflaza) and a broader rare disease pipeline, making it a directly comparable commercial-stage peer to ImmunoForge's rare neuromuscular focus.
  • BridgeBio Pharma: BridgeBio is a clinical-stage rare disease biotech pursuing multiple genetically targeted therapies, structurally similar to ImmunoForge in pursuing a broad pipeline of single-indication rare disease programs with multiple licensing/out-licensing opportunities.
  • Sarepta Therapeutics: Sarepta is the dominant commercial-stage biotech focused on Duchenne Muscular Dystrophy, directly overlapping with ImmunoForge's PF1801 (Froniglutide) and PF1804 (Pemziviptadil) DMD programs. Both companies target rare neuromuscular diseases with high unmet need and pursue FDA Orphan Drug Designations as a core regulatory strategy.
  • Amicus Therapeutics: Amicus is a clinical-to-commercial rare disease biotech using protein engineering and biologics to address diseases of protein misfolding and deficiency, sharing with ImmunoForge a protein-engineering-driven therapeutic approach and a focus on rare diseases with no approved disease-modifying treatments.
  • Ultragenyx Pharmaceutical: Ultragenyx is a clinical-to-commercial stage rare disease biotech developing biologics for genetic and metabolic diseases, with similar reliance on orphan drug exclusivity and a comparable pipeline-to-platform model. Their achondroplasia and short bowel programs directly overlap with ImmunoForge's PF1805 and PF1806.

Regional players

  • HanAll Biopharma: HanAll is a Korean clinical-stage biopharma with autoimmune and rare disease pipeline assets (e.g., batoclimab) and global out-licensing deals (with Immunovant, Roivant), making it the most directly comparable Korean regional peer to ImmunoForge in therapeutic focus and licensing-based GTM model.
  • GC Pharma: GC Pharma (formerly Green Cross) is a major Korean biopharma with a biologics and rare disease focus, comparable to ImmunoForge as a Korean-listed biopharma pursuing therapeutic biologics, though much larger with commercial-stage products.

Broad incumbents

  • Halozyme Therapeutics: Halozyme's ENHANZE platform is the leading commercial half-life extension technology (royalty-bearing deals with Roche, Pfizer, Janssen, etc.), making it the most directly comparable platform-licensing business model to ImmunoForge's ELP technology. Halozyme is more mature with a deep royalty stream from approved products.
  • BioMarin Pharmaceutical: BioMarin is an established rare disease biologics leader with a multi-product commercial portfolio and active late-stage pipeline, comparable in therapeutic focus (rare genetic disease) and biologic modality to ImmunoForge's pipeline, though much larger and commercially mature.
  • Ionis Pharmaceuticals: Ionis is a clinical-to-commercial antisense/RNA therapeutics biotech with deep rare disease focus, sharing with ImmunoForge a half-life/extended dosing engineering emphasis, multiple partnered programs, and a reliance on FDA ODD pathways. Both also pursue novel enabling delivery technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

ImmunoForge social profiles

Digital presence

ImmunoForge compliance and trust

Trust signal

Compliance5 records

ImmunoForge financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImmunoForge leadership team

Management profile

Number of profiles

Profiles5 records

ImmunoForge funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImmunoForge M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmunoForge

What does ImmunoForge do?

ImmunoForge is a clinical-stage biopharmaceutical company developing long-acting biologic drug candidates for rare neuromuscular, inflammatory, and metabolic diseases, using its proprietary ELP (Elastin-Like Polypeptide) half-life extension platform and LMT15 Blood-Brain Barrier shuttle platform. The company advances its own pipeline through Phase 2 clinical trials and generates revenue by out-licensing drug candidates and platform technologies to global pharmaceutical partners, while pursuing co-development agreements and NewCo structures.

Is ImmunoForge a public or private company?

ImmunoForge is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImmunoForge founded?

ImmunoForge was founded in 2017. It employs 1 to 10 people.

Where is ImmunoForge based?

ImmunoForge is headquartered in Seoul, South Korea, in the Asia region.

How does ImmunoForge make money?

Three revenue lines are on record. Licensing and Technology Transfer is the primary driver. The others are co-development and Partnership Revenue and newCo Investment Structures.

Who are ImmunoForge's main competitors?

Direct peers on record are PTC Therapeutics, BridgeBio Pharma, Sarepta Therapeutics, Amicus Therapeutics and Ultragenyx Pharmaceutical. Regional players are HanAll Biopharma and GC Pharma. Broad incumbents are Halozyme Therapeutics, BioMarin Pharmaceutical and Ionis Pharmaceuticals.

Does ImmunoForge have an API?

No public API is recorded for ImmunoForge.

What industry is ImmunoForge in?

ImmunoForge's product category is Clinical-stage Biopharmaceutical — Rare Disease Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comYear-end Report (Q4) July 2025 – June 2026Hamlet BioPharma reported Q4 2025–2026 net sales of zero and an EBITDA loss of KSEK 13,384. The company received EMA approval for its Phase III study of Alpha1H in bladder cancer and signed a clinical trial agreement with the University of Iowa. It is also discussing a partnership with a German pharmaceutical company for commercialization.GurufocusImmunoForge Selected for the Ministry of SMEs and Startups' 'GloBiotech company ImmunoForge has been selected for the Ministry of SMEs and Startups' Global TIPS R&D program, receiving KRW 5 billion in government funding over four years to advance its LMT platform. This initiative focuses on developing a hybrid lipid nanoparticle technology capable of penetrating the blood-brain barrier for central nervous system therapeutics. The company plans to utilize these funds to accelerate preclinical development and pursue global partnerships for technology transfer.AijournImmunoForge Selected for the Ministry of SMEs and Startups’ ‘Global TIPS R&D’ Program… “Expansion of the LMT Platform”Biotech company ImmunoForge has been selected for the Ministry of SMEs and Startups’ Global TIPS R&D program, securing KRW 5 billion in government funding over four years to develop its LMT platform. This technology combines Blood-Brain Barrier penetration with a one-month sustained-release formulation, aiming to accelerate preclinical development for CNS-targeted therapeutics. ImmunoForge intends to leverage this funding to pursue global partnerships and technology transfers for its differentiated delivery systems.PR NewswireImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"ImmunoForge has been selected for the 2026 Global TIPS R&D program organized by South Korea's Ministry of SMEs and Startups, securing KRW 5 billion in government funding over four years. The biotech company will utilize this capital to advance its proprietary LMT platform, which combines blood-brain barrier penetration with sustained-release capabilities for central nervous system therapeutics. ImmunoForge plans to leverage this development to pursue global partnerships and technology transfers with international pharmaceutical firms.PR Newswire APACImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"ImmunoForge has been selected for the Ministry of SMEs and Startups' Global TIPS R&D program, receiving KRW 5 billion in government funding over four years to develop a hybrid LNP platform for CNS therapeutics. The technology leverages Leptin receptor-mediated transcytosis to enable blood-brain barrier penetration and sustained release, following prior validation by winning Novo Nordisk's Open Innovation contest. ImmunoForge plans to utilize these funds for preclinical development and is actively pursuing global partnerships for collaborative research and technology transfer.YahooImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"ImmunoForge has been selected for the Ministry of SMEs and Startups' Global TIPS R&D program, securing KRW 5 billion in government funding over four years to advance its LMT platform. The biotech venture will utilize this support to develop a hybrid lipid nanoparticle technology combining blood-brain barrier penetration with sustained-release capabilities for central nervous system therapeutics.MorningstarImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"ImmunoForge was selected for the Ministry of SMEs and Startups' Global TIPS R&D program, receiving KRW 5 billion over four years. The company will expand its LMT platform, a BBB-penetrating hybrid LNP platform, for CNS-targeted therapeutics. It plans full-scale development and global partnerships.PR NewswireImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'ImmunoForge Co., Ltd. announced its proprietary LMT15 Platform, a next-generation Blood-Brain Barrier shuttle technology combining Leptin receptor-Mediated Transcytosis with the company's ELP long-acting technology for once-monthly CNS drug delivery. The platform was awarded first place at 'Novo Nordisk Partnering Day 2026' in South Korea, co-hosted by Novo Nordisk Pharma Korea, KHIDI, and Novo Holdings, out of numerous domestic biotech participants. ImmunoForge has filed a patent for LMT15 and is initiating full-scale CNS pipeline development, while also advancing clinical-stage assets PF1801 (Phase 2 for polymyositis/dermatomyositis) and PF1804 (Phase 2 for DMD cardiomyopathy with FDA IND approval).MorningstarImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company, announced its LMT15 Platform, a next-generation Blood-Brain Barrier shuttle technology that combines high BBB permeability with proprietary long-acting ELP technology for once-monthly CNS drug formulations. The platform's innovative potential was validated when ImmunoForge won first place at 'Novo Nordisk Partnering Day Korea 2026' among numerous domestic biotech participants, earning expert feedback, investment mentoring, and collaboration opportunities from Novo Nordisk and Novo Holdings. The company has filed a patent for LMT15 and is initiating full-scale CNS pipeline development while advancing its clinical-stage assets PF1801 for inflammatory myopathies and PF1804 for DMD cardiomyopathy.YahooImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company, announced its proprietary LMT15 Platform, a next-generation Blood-Brain Barrier shuttle technology that combines Leptin receptor-Mediated Transcytosis with its long-acting ELP (Elastin-Like Polypeptide) technology to enable efficient brain penetration and once-monthly dosing for CNS therapies. The platform was awarded first place at Novo Nordisk Partnering Day Korea 2026, earning ImmunoForge expert feedback, investment mentoring, and collaboration networking opportunities from Novo Nordisk and Novo Holdings. The company has filed a patent for LMT15, raised approximately $32 million in cumulative investment, and is advancing its CNS pipeline alongside clinical-stage assets PF1801 (Phase 2 for Polymyositis/Dermatomyositis) and PF1804 (Phase 2 for DMD cardiomyopathy, FDA IND-approved with Orphan Drug Designation).